Fermer le menu


Member of Lyonbiopole


OREGA Biotech specializes in the discovery and the development of first-in-class monoclonal antibodies for cancer immunotherapy.

OREGA Biotech’s business strategy is to bring its R&D programs up to proof of concept and then enter into a partnership and license agreement with larger biotechs or pharmaceutical companies at early stage.

The company is building on a strong IP strategy, high level scientific publications and relies on a strong academic and industrial network. The company is managed by Gilles Alberici, PhD, CEO and Jeremy Bastid, PhD, COO.


Strategic application domain: Human Medicine

Application market: Oncology

Type of activity: Therapeutics, Pharma or Biotech

Technologies: Antibodies - Protein - Peptide

Created on march 9th, 2010 - 11 employees



Espace Europeen, Bat G, 15 chemin du Saquin 69130 Ecully



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.